You searched for side effects - Page 24 of 311 - Medivizor
Navigation Menu

Evaluating the long-term effectiveness and safety of enzalutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

Evaluating the long-term effectiveness and safety of enzalutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

Posted by on Jul 7, 2024 in Prostate cancer | 0 comments

In a nutshell This study reported the long-term effectiveness and safety of enzalutamide (Xtandi) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that enzalutamide in combination with ADT improved the overall survival over the long term with...

Read More

Evaluating the long-term effectiveness and safety of adding abiraterone acetate and prednisolone with or without enzalutamide in patients with metastatic prostate cancer starting androgen-deprivation therapy.

Evaluating the long-term effectiveness and safety of adding abiraterone acetate and prednisolone with or without enzalutamide in patients with metastatic prostate cancer starting androgen-deprivation therapy.

Posted by on May 26, 2024 in Prostate cancer | 0 comments

In a nutshell The study evaluated the long-term effectiveness and safety outcomes of adding abiraterone acetate (AA; Zytiga) and prednisolone (P; Deltasone) with or without enzalutamide (Xtandi) in patients with metastatic prostate cancer (PC) starting androgen-deprivation therapy (ADT). The data showed that enzalutamide and AA+P should not be combined...

Read More

Evaluating the effectiveness and safety of immune checkpoint inhibitors given before surgery for the treatment of resectable mucosal melanoma.

Evaluating the effectiveness and safety of immune checkpoint inhibitors given before surgery for the treatment of resectable mucosal melanoma.

Posted by on Oct 22, 2023 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of immune checkpoint inhibitors (ICIs) given before surgery for the treatment of patients with resectable mucosal melanoma. The data showed that ICIs given before surgery were effective with manageable side effects for these patients. Some background Melanoma is an aggressive type of skin...

Read More

Comparing the effectiveness and safety of chemotherapy-based combination therapies as first-line treatment for advanced non-small cell lung cancer with negative PD-L1.

Comparing the effectiveness and safety of chemotherapy-based combination therapies as first-line treatment for advanced non-small cell lung cancer with negative PD-L1.

Posted by on Oct 22, 2023 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of chemotherapy-based combination therapies for the treatment of patients with advanced non-small cell lung cancer (NSCLC) with negative PD-L1 expression. The data showed that pembrolizumab (Keytruda) plus chemotherapy combination was the best treatment regimen for improving overall survival...

Read More

Evaluating the effectiveness and safety of TAS-102 plus Yttrium-90 radioembolization for the treatment of patients with colorectal cancer liver metastasis.

Evaluating the effectiveness and safety of TAS-102 plus Yttrium-90 radioembolization for the treatment of patients with colorectal cancer liver metastasis.

Posted by on Oct 22, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of TAS-102 (Lonsurf; trifluridine-tipiracil) plus Yttrium-90 (Y-90) radioembolization (RE) for patients with colorectal cancer liver metastasis (CRLM) who are unresponsive to chemotherapy. The data showed that TAS-102 plus RE was safe and effective in these patients. Some background...

Read More

Comparing the effectiveness of combined therapy of bortezomib, melphalan, and prednisone with versus without daratumumab in patients with multiple myeloma ineligible for a transplant

Comparing the effectiveness of combined therapy of bortezomib, melphalan, and prednisone with versus without daratumumab in patients with multiple myeloma ineligible for a transplant

Posted by on Sep 17, 2023 in Multiple Myeloma | 0 comments

In a nutshell The study evaluated the effectiveness of combined therapy of bortezomib (Velcade), melphalan (Alkeran), and prednisone (Deltasone) with (D-VMP) versus without (VMP) daratumumab (Darzalex) in transplant-ineligible patients newly diagnosed with multiple myeloma (MM). The study concluded that D-VMP was more effective than using...

Read More

Evaluating the effectiveness and safety of continuous subcutaneous foslevodopa-foscarbidopa for the treatment of motor fluctuations in patients with Parkinson’s disease.

Evaluating the effectiveness and safety of continuous subcutaneous foslevodopa-foscarbidopa for the treatment of motor fluctuations in patients with Parkinson’s disease.

Posted by on Sep 17, 2023 in Parkinson's Disease | 0 comments

In a nutshell This study evaluated the effectiveness and safety of continuous subcutaneous foslevodopa-foscarbidopa (ABBV-951) for the treatment of motor fluctuations in patients with Parkinson’s disease (PD). The data showed that continuous subcutaneous foslevodopa-foscarbidopa significantly improved motor fluctuations in these patients. Some...

Read More

Comparing the effectiveness and safety of 5 injections of OnabotulinumtoxinA versus the standard 20 injections for the treatment of patients with overactive bladder.

Comparing the effectiveness and safety of 5 injections of OnabotulinumtoxinA versus the standard 20 injections for the treatment of patients with overactive bladder.

Posted by on Sep 17, 2023 in Overactive bladder | 0 comments

In a nutshell This study compared the effectiveness and safety of 5 injections of onabotulinumtoxinA (OBTA; Botox) versus the standard 20 injections for the treatment of patients with overactive bladder (OAB). The study found that a reduced technique of 5 injections of OBTA was safe and as effective as the standard technique of 20 injections for the...

Read More

Does statin use improve survival outcomes in men with advanced prostate cancer undergoing androgen deprivation therapy?

Does statin use improve survival outcomes in men with advanced prostate cancer undergoing androgen deprivation therapy?

Posted by on Sep 17, 2023 in Prostate cancer | 0 comments

In a nutshell This study evaluated the association between statin (cholesterol-lowering drugs) use and survival outcomes in men with advanced prostate cancer (PC) undergoing androgen deprivation therapy (ADT). The data showed that statin use improved the survival outcomes in these patients. Some background Metastatic prostate cancer (PC) is a form of...

Read More

Reducing chemotherapy-induced toxicities in patients with breast cancer using anti-diabetes medication metformin.

Reducing chemotherapy-induced toxicities in patients with breast cancer using anti-diabetes medication metformin.

Posted by on Sep 17, 2023 in Breast cancer | 0 comments

In a nutshell This study investigated the beneficial effects of co-administering anti-diabetes medication metformin (Glucophage) and doxorubicin (Adriamycin)-cyclophosphamide (Cytoxan) with paclitaxel (Taxol) (AC-T) chemotherapy in non-diabetic patients with breast cancer (BC). The data showed that metformin reduced the occurrence and severity of...

Read More

Evaluating the effectiveness and safety of maintenance therapy with panitumumab plus FOLFIRI in patients with RAS wild-type metastatic colorectal cancer.

Evaluating the effectiveness and safety of maintenance therapy with panitumumab plus FOLFIRI in patients with RAS wild-type metastatic colorectal cancer.

Posted by on Aug 27, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of panitumumab (Vectibix) rechallenge when added to maintenance therapy with FOLFIRI {fluorouracil (FU; Adrucil), folinic acid (FA; Leucovorin), irinotecan (Camptosar)} in patients with RAS wild-type metastatic colorectal cancer (mCRC). The data showed that maintenance therapy with...

Read More

Evaluating the long-term effectiveness and safety of daratumumab plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.

Evaluating the long-term effectiveness and safety of daratumumab plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.

Posted by on Aug 27, 2023 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the long-term effectiveness and safety of daratumumab (D; Darzalex) plus bortezomib (V; Velcade) and dexamethasone (d; Decadron) (D-Vd) regimen in patients with relapsed or refractory (r/r) multiple myeloma (MM). The data showed that the D-Vd regimen significantly increased the overall survival in these patients. Some...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2025 Medivizor